article · Journal of Tianjin University Science and Technology
Abstract Introduction: Oral squamous cell carcinoma (OSCC) remains a leading global malignancy with low survival expectancy due to its evasion from the immune response. Immune checkpoint molecules such as programmed death ligand-1 (PDL-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) contribute to tumor immune evasion. Curcumin (Cr), combined with the bioenhancer piperine (Pip), exhibits antiproliferative and anti-inflammatory activities, yet its influence on immune checkpoint expression within a carcinogen-induced tumor microenvironment remains poorly characterized. Aim: This study evaluated the short-term effects of an intraperitoneal Cr-Pip combination on tumor progression, systemic cytokine balance, histopathological architecture, and PDL-1/CTLA-4 expression in a DMBA-induced hamster OSCC model. Methodology: Twenty male Syrian hamsters were divided into a negative control group (A), a DMBA-induced OSCC positive control group (B), and a DMBA-induced OSCC group receiving one week of intraperitoneal Cr (80 mg/kg) and Pip (1 mg/kg) (C). Tumor size, serum IL-10 and TNF-α, histopathological features, and immunohistochemical PDL-1/CTLA-4 expression were assessed and statistically compared. Conclusion: Cr-Pip treatment significantly reduced tumor burden and produced a more cohesive, less invasive histological pattern, accompanied by decreased IL-10, elevated TNF-α, and a significant increase in PDL-1 and CTLA-4 expression. These findings indicate that Cr-Pip modulates both tumor invasive behavior and the immune checkpoints, reflecting a shift toward local immune activation as well as evidence of partial tumor regression.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.5281/zenodo.22122653
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.